2025 Q1 Planned trials
- ALC9: Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
- CE10 VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
- CO33: Botensilimab + Balstilimab or Botensilimab Alone vs Best Supportive Care as Therapy in Chemo-refractory, Advanced, Colorectal Adenocarcinoma: The BATTMAN Trial
- HE2 STRIDE: (durvalumab + tremelimumab) with Lenvatinib vs STRIDE Alone in Patients with Unresectable Hepatocellular Carcinoma (SLIDE-HCC)
- MD1 CALMS: Combination Therapy with Luspatercept in Lower Risk MDS CTEP approval: 2024AUG27 (date of US Steering Committee Evaluation)
- PAC5: Lanreotide for the Prevention of Postoperative Pancreatic Fistula
- SC30: Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Platform Trial - RATIONAL-PT
- SC31: Using SMART to optimize the stepped care delivery of TEMPO – a Tailored, dyadic, wEb-based physical activity and self-Management PrOgram for men with prostate cancer and their caregivers (TEMPO)
- SR8: NeoAdjuvant-only or Peri-operative cemiplimab in high-grade localised soft-tissue SARcoma (NAPStAR)
- HN14: Delayed Reduced Volume and Dose Elective Ratiotherapy (REVERT) in Patients with HNSCC
- MA42: No Chemotherapy in Intermediate-risk HR + HER2- Early Breast Cancer Treated with Ribociclib (NoLEEta)
2025 Q1 recently activated
- BLC6 MODERN: An Integrated Phase 2/3 and Phase 3 Trial of MRD-Based Optimization of Adjuvant Therapy in Urothelial Cancer More >>
- BR38: Radiotherapy to Block (CURB2) Oligoprogression In Metastatic Non-Small-Cell Lung Cancer More >>
- HN13: Comparing Palliative Stereotactic Body Radiotherapy vs. Palliative Standard Radiotherapy in Patients with Advanced Head and Neck Cancer More >>
- ME17: for Fecal Microbiota Transplantation in Combination with Immune Checkpoint Blockade in Patients with Advanced Melanoma More >>
- PR26: Addition of Docetaxel to Androgen Receptor Pathway Inhibitors in Patients with Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response (TRIPLE-SWITCH) More >>
- SKC1: Neoadjuvant Immunotherapy with Response-Adapted Treatment vs Standard-Of-Care Treatment For Resectable Stage III/IV Cutaneous Squamous Cell Carcinoma More >>
- SRC8: Doxorubicin + Pembrolizumab vs Doxorubicin for Treatment of Undifferentiated Pleomorphic Sarcoma (UPS) and Related Poorly Differentiated Sarcomas More >>